# Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

> **NCT06157060** · — · RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 255 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Resectable

## Interventions

- **DIAGNOSTIC_TEST:** circulating tumor DNA

## Key facts

- **NCT ID:** NCT06157060
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2026-11-20
- **Final completion:** 2028-11-30
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06157060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06157060, "Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06157060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*